Aspirin-triggered lipid mediators

• US 7,709,669 B2
• Filed: 01/18/2006
• Issued: 05/04/2010
• Est. Priority Date: 02/16/2000
• Status: Expired due to Term

• Current Assignee: Brigham and Women's Hospital Incorporated
• Original Assignee: Brigham and Women's Hospital Incorporated
• Inventors: Serhan, Charles N., Clish, Clary B.
• Primary Examiner(s): Kumar; Shailendra
• Application Number:
  US11/334,330
• Publication Number:
  US 20070049639A1
• Time in Patent Office: 1,567 Days
• Field of Search: 554/224, 514/549, 514/560, 562/579
• US Class Current: 554/224
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 17/08 Antiseborrheics
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/14 Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
• CPC Class Codes: C07B 2200/07 Optical isomers
• CPC Class Codes: C07C 59/42 : containing hydroxy or O-metal groups
• CPC Class Codes: C07C 59/58 : containing ether groups, groups, groups, or groups
• CPC Class Codes: C07C 69/732 : of unsaturated hydroxy carboxylic acids
• CPC Class Codes: C12P 7/6427 : Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
• CPC Class Codes: C12P 7/6436 : Fatty acid esters
• CPC Class Codes: C12P 7/6472 : containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
• CPC Class Codes: Y02P 20/55 : Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Aspirin triggered lipid mediators (ATLMs) are disclosed which are useful for the treatment of prevention of inflammation associated with various diseases, including ischemia.

Claims

1. A purified compound having the formula:

2. The compound of claim 1, wherein each occurrence of P is H.

3. The compound of claim 1, wherein R is H.

4. The compound of claim 1, wherein the C-5 carbon has an S configuration, the C-12 carbon has an R configuration and the C-18 carbon has an R configuration.

12. The pharmaceutical composition of claim 1, wherein the C-5 carbon has an S configuration, the C-12 carbon has an R configuration and the C-18 carbon has an R configuration.

13. The compound of claim 2, wherein R is H.

14. The compound of claim 2, wherein the C-5 carbon has an S configuration, the C-12 carbon has an R configuration and the C-18 carbon has an R configuration.

15. The compound of claim 3, wherein the C-5 carbon has an S configuration, the C-12 carbon has an R configuration and the C-18 carbon has an R configuration.

16. The compound of claim 13, wherein the C-5 carbon has an S configuration, the C-12 carbon has an R configuration and the C-18 carbon has an R configuration.

5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the formula:

6. The pharmaceutical composition of claim 5, wherein each occurrence of P is H.

7. The pharmaceutical composition of claim 5, wherein R is H.

8. The pharmaceutical composition of claim 5, wherein the C-5 carbon has an S configuration, the C-12 carbon has an R configuration and the C-18 carbon has an R configuration.

9. The pharmaceutical composition of claim 6, wherein R is H.

10. The pharmaceutical composition of claim 6, wherein the C-5 carbon has an S configuration, the C-12 carbon has an R configuration and the C-18 carbon has an R configuration.

11. The pharmaceutical composition of claim 7, wherein the C-5 carbon has an S configuration, the C-12 carbon has an R configuration and the C-18 carbon has an R configuration.